Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuya Yoshimoto

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Nature Communications|November 25, 2017
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cellsHiro Sato, Atsuko Niimi, Takaaki Yasuhara, et al.
Communications Medicine|August 15, 2023
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancerKosaku Mimura, Takashi Ogata, Yuya Yoshimoto, et al.
Oncology Letters|April 19, 2021
Analysis of radiotherapy-induced alteration of CD8<sup>+</sup> T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinomaYasumasa Mori, Hiro Sato, Takuya Kumazawa, et al.
Oncotarget|September 18, 2018
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapyEndang Nuryadi, Yasushi Sasaki, Yoshihiko Hagiwara, et al.
Cytotherapy|July 24, 2023
Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG)Rishu Takimoto, Takashi Kamigaki, Hisao Ito, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Nature Communications|November 25, 2017
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cellsHiro Sato, Atsuko Niimi, Takaaki Yasuhara, et al.
Communications Medicine|August 15, 2023
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancerKosaku Mimura, Takashi Ogata, Yuya Yoshimoto, et al.
Oncology Letters|April 19, 2021
Analysis of radiotherapy-induced alteration of CD8<sup>+</sup> T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinomaYasumasa Mori, Hiro Sato, Takuya Kumazawa, et al.
Oncotarget|September 18, 2018
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapyEndang Nuryadi, Yasushi Sasaki, Yoshihiko Hagiwara, et al.
Cytotherapy|July 24, 2023
Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG)Rishu Takimoto, Takashi Kamigaki, Hisao Ito, et al.
Pageof 6